Health Technology

Peptidream, Inc.

In the news

Japan's university startups top 2,000 for first time Mar 9, 2018
Out of the lab, into the market Feb 5, 2018
Drugmakers are drawn to Japan's laboratory in space Jan 29, 2018
Japanese bioventures receiving healthy dose of investor funds Jan 24, 2018
Univ. of Tokyo startups are targets of new $220m tech fund Jan 24, 2018

Business Summary

PeptiDream, Inc. engages in the biopharmaceutical business that includes research and development of non-standard peptide therapeutics. It produces macrocyclic peptides based on its proprietary Peptide Discovery Platform System (PDPS). The company was founded by Kiichi Kubota and Hiroaki Suga on July 3, 2006 and is headquartered in Kawasaki, Japan.

Financial Highlights

Dec 2021	JPY	USD
Revenue	9,365.96M	85.24M
Gross Profit	6,937.89M	63.14M
Operating income	4,418.14M	40.21M
Income before tax	4,823.65M	43.90M
Net income	3,606.40M	32.82M
EBITDA	5,051.15M	45.97M
Diluted EPS	27.77	0.25
Dividends Per Share	0	0
Total Assets	26,619.16M	231.15M
Total liabilities	1,620.57M	14.07M
Total equity	24,998.59M	217.08M
Operating cash flow	6,654.70M	60.56M
	Currency in JPY	Currency in USD

Historical Data

JPY | USD

	Jun 2017	Jun 2018	Dec 2019	Dec 2020	Dec 2021
Revenue	4,895.74M	6,426.89M	2,074.67M	11,677.25M	9,365.96M
Gross Profit	3,530.02M	4,648.26M	661.06M	9,459.96M	6,937.89M
Operating income	2,490.41M	2,978.48M	-1,774.33M	6,991.32M	4,418.14M
Income before tax	2,624.15M	3,151.73M	-1,413.07M	6,020.02M	4,823.65M
Net income	1,890.75M	2,335.21M	-976.92M	4,448.35M	3,606.40M
EBITDA	2,685.28M	3,491.82M	-1,261.79M	7,562.34M	5,051.15M
Diluted EPS	14.56	17.79	-7.80	34.26	27.77
Dividends Per Share	0	0	0	0	0
Total Assets	13,628.45M	16,512.83M	17,817.34M	26,266.72M	26,619.16M
Total liabilities	1,447.65M	1,804.11M	839.05M	5,049.72M	1,620.57M
Total equity	12,180.80M	14,708.71M	16,978.28M	21,217.00M	24,998.59M
Operating cash flow	1,530.77M	1,022.71M	241.98M	1,732.73M	6,654.70M

	Jun 2017	Jun 2018	Dec 2019	Dec 2020	Dec 2021
Revenue	44.87M	58.24M	19.03M	109.36M	85.24M
Gross Profit	32.35M	42.12M	6.06M	88.60M	63.14M
Operating income	22.82M	26.99M	-16.27M	65.48M	40.21M
Income before tax	24.05M	28.56M	-12.96M	56.38M	43.90M
Net income	17.33M	21.16M	-8.96M	41.66M	32.82M
EBITDA	24.61M	31.64M	-11.57M	70.82M	45.97M
Diluted EPS	0.13	0.16	-0.07	0.32	0.25
Dividends Per Share	0	0	0	0	0
Total Assets	121.29M	149.07M	163.95M	254.41M	231.15M
Total liabilities	12.88M	16.28M	7.72M	48.91M	14.07M
Total equity	108.40M	132.79M	156.22M	205.50M	217.08M
Operating cash flow	14.03M	9.26M	2.21M	16.22M	60.56M

Valuation Measures

Dec 2021
PER	90.96
ROA	13.63%
ROE	15.60%
Operating margin	47.17%
Profit margin	38.50%

Key executives

President, CEO & Representative Director: Patrick Crawford Reid
Chief Operating Officer, Director & Vice President: Keiichi Masuya
Chief Financial Officer, Director & Vice President: Kiyofumi Kaneshiro
Director-Public Relations & Investor Relations: Yuko Okimoto

Shareholders

KUBOTA KIICHI (10.4%)
SUGA HIROAKI (9.3%)
Taiyo Pacific Partners LP (7.2%)
JOHCM (Singapore) Pte Ltd. (4.4%)
Sumitomo Mitsui Trust Asset Management Co., Ltd. (3.6%)
REID PATRICK C (3.4%)
MURAKAMI HIROSHI /PEPTIDREAM INC/ (3.3%)
Invesco Advisers, Inc. (2.3%)
Baillie Gifford & Co. (2.3%)
Nomura Asset Management Co., Ltd. (2.2%)

Contact Details

Website:http://www.peptidream.com
Address: 3-25-23 Tonomachi, Kawasaki-Ku, Kawasaki, 210-0821, Japan
Phone: +81.44.270.1300

Related Companies

PeptiAID, Inc.
Fujifilm Toyama Chemical /Radiopharmaceutical Bus/
Peptidream Board Incentive Plan
Peptidream Employee Incentive Plan
PharmaDesign, Inc. (Japan) /Pharma Research Bus/
PharmaDesign, Inc. (Japan)

Competitors

Aileron Therapeutics, Inc.
Apellis Pharmaceuticals, Inc.
Bicycle Therapeutics Plc Sponsored ADR
Protagonist Therapeutics, Inc.
UCB S.A.
Avidity Biosciences Inc

Last Updated on 26 Sep, 2022